

# Bacterial supplementation as treatment for the irritable bowel syndrome: a randomised double-blind placebo-controlled study

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 16/02/2015	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr S Pathmakanthan

**Contact details**  
GI Medicine  
Selly Oak Hospital  
Birmingham  
United Kingdom  
B29 6JD

## Additional identifiers

**Protocol serial number**  
N0265122367

## Study information

**Scientific Title**  
Bacterial supplementation as treatment for the irritable bowel syndrome: a randomised double-blind placebo-controlled study

**Study objectives**

To assess the tolerance and efficacy of Synbiotic Cocktail 2000 in symptom reduction in the irritable bowel syndrome.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Double-blind randomised placebo-controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Digestive System: Irritable bowel syndrome (IBS)

**Interventions**

ASSESSMENT ON ADMISSION INTO TRIAL: History and examination, normal blood tests and a previously normal flexible sigmoidoscopy.

ASSESSMENT DURING STUDY PERIOD: All patients will be randomised to receive either the placebo or Synbiotic cocktail 2000 daily for 8 weeks. Prior to this period, there will be a run in period of 2 weeks where patients will record baseline gastrointestinal symptoms on a weekly basis as well as bowel frequency and consistency on a daily basis. A previously validated patient diary will be used scoring abdominal pain, bloating, number and consistency of stool and level of flatulence completed on a weekly basis. After the 2 week run in period, a study period involving Synbiotic or placebo intake will last for 8 weeks. A final questionnaire would be sent out to all patients 6 months post study period, using the same format. Prior to commencement and directly after treatment or placebo period, patients will undergo a hydrogen breath test to ensure bacterial supplementation has not resulted in bacterial overgrowth.

REMOVAL FROM STUDY: Patients may be removed from the study if one or more of the following occurs: Protocol violation or non-compliance on part of the patient, refusal of the patient to continue treatment and a decision by the investigator that termination is in the patient's best medical interest (or a significant unrelated medical illness or complication).

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Synbiotic Cocktail 2000

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

13/04/2008

## Eligibility

**Key inclusion criteria**

1. Any patient seen in gastroenterology outpatient clinics at University Hospital Birmingham who fulfils the Rome criteria II for IBS would be offered entry into the trial
2. Patients without a history of malabsorption, previous abdominal surgery, diverticulitis or other organic intestinal disease

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

All

**Sex**

All

**Key exclusion criteria**

1. Pregnancy
2. Any form of mental disorder
3. Severe systemic illness

**Date of first enrolment**

13/04/2003

**Date of final enrolment**

13/04/2008

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**GI Medicine**  
Birmingham  
United Kingdom  
B29 6JD

## **Sponsor information**

**Organisation**  
Department of Health (UK)

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
University Hospital Birmingham NHS Trust (UK)

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration